Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Zervimesine (CT1812) in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
SHINE Trial. 11/07/23- Completed enrollment. 7/29/24- Presented Ph2 POC data at AAIC 2024. 3/25/25- Present biomarker data at AD/PD 2025. 7/10/25- End-of-Ph2 meeting with FDA completed. 8/12/25- Received EoPh2 minutes confirming proposed Ph3 design may support NDA. 11/06/25:- FDA alignment on registrational path; Ph3 study design to be presented at CTAD'25. 03/26/26:- EMA scientific advice completed; registrational AD program decision to follow START Ph2 results expected 2027. 05/07/26:- Company reiterates commitment to Alzheimer's disease program; START Phase 2 results in 2027 expected to guide registrational strategy. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.